Type 2 diabetes mellitus: a review of current trends.
暂无分享,去创建一个
A. Olokoba | O. A. Obateru | L. Olokoba | Abdulfatai B Olokoba | Olusegun A Obateru | Lateefat B Olokoba | O. Obateru
[1] In-kyu Lee,et al. Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP , 2008, Diabetes.
[2] P. Zimmet,et al. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives , 2012, Nature Reviews Endocrinology.
[3] S. Barlow,et al. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. , 2007, Pediatrics.
[4] G. Lopaschuk,et al. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. , 2006, American journal of physiology. Endocrinology and metabolism.
[5] R. Urban,et al. Management of blood glucose in type 2 diabetes mellitus. , 2009, American family physician.
[6] R. D. White,et al. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. , 2004, American family physician.
[7] Anson,et al. DIET , LIFESTYLE , AND THE RISK OF TYPE 2 DIABETES MELLITUS IN WOMEN , 2001 .
[8] A. Scheen. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update. , 2005, Drug safety.
[9] C. Wiener. Harrison's principles of internal medicine , 2013 .
[10] E. Oetjen. Management of type 2 diabetes: new and future developments in treatment , 2012 .
[11] J. Blicklé,et al. Meglitinide analogues: a review of clinical data focused on recent trials. , 2006, Diabetes & metabolism.
[12] A. Barnett,et al. DPP‐4 inhibitors and their potential role in the management of type 2 diabetes , 2006, International journal of clinical practice.
[13] P. Zimmet,et al. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.
[14] J. Stockman,et al. Association of Urinary Bisphenol A Concentration With Medical Disorders and Laboratory Abnormalities in Adults , 2010 .
[15] M. Patlak. New Weapons to Combat an Ancient Disease: Treating Diabetes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] D. Yach,et al. The global burden of chronic diseases: overcoming impediments to prevention and control. , 2004, JAMA.
[17] S. Jabbour,et al. Management of diabetes mellitus in the elderly , 2011, Current opinion in endocrinology, diabetes, and obesity.
[18] K. Rother. Diabetes treatment--bridging the divide. , 2007, The New England journal of medicine.
[19] J. Lovejoy. The influence of dietary fat on insulin resistance , 2002, Current diabetes reports.
[20] G. Bray,et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. , 1995, The American journal of medicine.
[21] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[22] J. Rosenstock,et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial , 2010, The Lancet.
[23] Mark I McCarthy,et al. Genomics, type 2 diabetes, and obesity. , 2010, The New England journal of medicine.
[24] L. Abenhaim,et al. Rates of hypoglycemia in users of sulfonylureas. , 1997, Journal of clinical epidemiology.
[25] T. Darsow,et al. Incretin-based therapies , 2012, Journal of diabetes.
[26] K. Narayan,et al. The Global Burden of Diabetes , 2010 .
[27] R. Klein,et al. Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.
[28] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[29] E. Cummins,et al. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. , 2007, Health technology assessment.
[30] F. Vinicor,et al. Aging Americans and diabetes. A public health and clinical response. , 2004, Geriatrics.
[31] K. Fujioka. Pathophysiology of Type 2 Diabetes and the Role of Incretin Hormones and Beta‐Cell Dysfunction , 2007, JAAPA : official journal of the American Academy of Physician Assistants.
[32] J. Shaw,et al. Global and societal implications of the diabetes epidemic , 2001, Nature.
[33] R. Sinha,et al. Body Mass Index and Diabetes in Asia: A Cross-Sectional Pooled Analysis of 900,000 Individuals in the Asia Cohort Consortium , 2011, PloS one.
[34] Sridevi Alla,et al. Diabetes in Sub-Saharan Africa: Kenya, Mali, Mozambique, Nigeria, South Africa and Zambia , 2008, International journal of diabetes in developing countries.
[35] P. Rorsman,et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. , 1998, Diabetes.
[36] A. Ahmed. History of diabetes mellitus. , 2002, Saudi medical journal.
[37] C. R. Kahn,et al. Insulin Action, Diabetogenes, and the Cause of Type II Diabetes , 1994, Diabetes.
[38] Robertson Rp. Antagonist: diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. , 1995, The Journal of laboratory and clinical medicine.
[39] B. Murtagh,et al. Present and Future Perspectives , 2014 .
[40] E. Bonora,et al. Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man , 1999, International Journal of Obesity.
[41] David Edelman,et al. Tests for Screening and Diagnosis of Type 2 Diabetes , 2009, Clinical Diabetes.
[42] N. Wareham,et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the EPIC-Norfolk cohort: implications for preventive strategies , 2010 .
[43] J. Shaw,et al. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.
[44] C. Cameron,et al. Cost-effectiveness of insulin analogues for diabetes mellitus , 2009, Canadian Medical Association Journal.
[45] R. Pratley,et al. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes , 2007, Current medical research and opinion.
[46] Philippe Froguel,et al. Genetics of obesity and the prediction of risk for health. , 2006, Human molecular genetics.
[48] R. Luben,et al. Incidence of Type 2 Diabetes Using Proposed HbA1c Diagnostic Criteria in the European Prospective Investigation of Cancer–Norfolk Cohort , 2011, Diabetes Care.
[49] J. Cornuz,et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. , 2007, JAMA.
[50] P. García-Rovés. RETRACTED: Mitochondrial pathophysiology and type 2 diabetes mellitus , 2011, Archives of physiology and biochemistry.
[51] Andrzej Bartke,et al. The Endocrine System , 1998, Alcohol health and research world.
[52] E. Liao. Management of type 2 diabetes: new and future developments in treatment. , 2012, The American journal of medicine.
[53] Richard Barnett,et al. Diabetes mellitus. , 1993, The Medical journal of Australia.
[54] W. Ray,et al. Individual Sulfonylureas and Serious Hypoglycemia in Older People , 1996, Journal of the American Geriatrics Society.
[55] Ho-Young Son,et al. Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.
[56] K. Shimamoto,et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance , 2009, The Lancet.